Viking Therapeutics, Inc.
VKTX
$33.80
-$0.64-1.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 50.71M | 48.28M | 48.39M | 52.36M | 57.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 560.02M | 502.00M | 393.34M | 274.84M | 212.84M |
| Operating Income | -560.02M | -502.00M | -393.34M | -274.84M | -212.84M |
| Income Before Tax | -534.80M | -472.34M | -359.64M | -237.39M | -171.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -534.80 | -472.34 | -359.64 | -237.39 | -171.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -534.80M | -472.34M | -359.64M | -237.39M | -171.55M |
| EBIT | -560.02M | -502.00M | -393.34M | -274.84M | -212.84M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4.66 | -4.15 | -3.18 | -2.12 | -1.53 |
| Normalized Basic EPS | -2.91 | -2.59 | -1.99 | -1.32 | -0.96 |
| EPS Diluted | -4.66 | -4.15 | -3.18 | -2.12 | -1.53 |
| Normalized Diluted EPS | -2.91 | -2.59 | -1.99 | -1.32 | -0.96 |
| Average Basic Shares Outstanding | 458.16M | 454.03M | 450.53M | 447.87M | 446.46M |
| Average Diluted Shares Outstanding | 458.16M | 454.03M | 450.53M | 447.87M | 446.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |